Premier Pharmacy Labs Inc recalls Neostigmine Methylsulfate (single dose syringe) 1 mg per mL 5 mg per 5 mL…
The stated reason: Stability Date Doesn't Support Expiry: labeling error indicating a beyond use date that exceeds current stability data.
Premier Pharmacy Labs Inc began a drug recall on August 10, 2017 whose reported distribution included Ohio. FDA
What the record shows
FDA graded it Class II — use may cause temporary or medically reversible health consequences. Quantity affected: 1610 syringes. The recall is listed as terminated. FDA
Context
By the numbers
- Date of record: August 10, 2017 FDA
- Recall number: D-0129-2018 FDA
- Recalls in this action: 1 FDA
- Recalling firm: Premier Pharmacy Labs Inc FDA
- Product: Neostigmine Methylsulfate (single dose syringe) 1 mg per mL 5 mg per 5 mL Injectable Hospital/Office Use Only… FDA
- Reason for recall: Stability Date Doesn't Support Expiry: labeling error indicating a beyond use date that exceeds current stability data. FDA
Assembled mechanically from the source filing and The Lantern's own record database — no AI-written prose. Every figure above appears verbatim in the cited record, which is linked on this page. FDA
Sources
The source filing
| Recall number | D-0129-2018 |
|---|---|
| Recalls in this action | 1 |
| Recalling firm | Premier Pharmacy Labs Inc |
| Product | Neostigmine Methylsulfate (single dose syringe) 1 mg per mL 5 mg per 5 mL Injectable Hospital/Office Use Only Compounded by: Premier Pharmacy Labs., Inc. 8265 Commercial Way Weeki Wachee, FL 34613, NDC# 69623-234-15 |
| Reason for recall | Stability Date Doesn't Support Expiry: labeling error indicating a beyond use date that exceeds current stability data. |
| Classification | Class II — use may cause temporary or medically reversible health consequences |
| Recall type | drug |
| Quantity | 1610 syringes |
| Status | Terminated |
| Voluntary or mandated | Voluntary: Firm initiated |
| Initiated | 20170810 |
| Reported | 20171227 |
| Distribution | Michigan, Maryland, Minnesota, North Carolina, Ohio, Florida |
| Firm location | Weeki Wachee, FL, United States |
Published by U.S. Food and Drug Administration (openFDA). This is the agency's public filing as The Lantern received it, shown with its fields named in plain English.